mortality/aging
• while mice are present in Mendelian ratios at E12, fewer than expected mice survive after weaning
|
reproductive system
• enlarged epididymal canal in male mice
|
• in male mice
|
homeostasis/metabolism
N |
• fasted male mice exhibit normal serum cholesterol levels
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in random-fed male mice starting at 9 weeks and worsening with age
|
• in 4 month old fasted male mice
• however, pioglitazone treatment improves phenotype
|
• at 2 months in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in 4 month old male mice
|
• in 4 month old male mice
• however, pioglitazone treatment improves insulin sensitivity
|
• at 2 months in the serum of male mice
• however, pioglitazone treatment improves phenotype
|
• male mice exhibit increased triacylglycerol-rich lipoprotein clearance compared with wild-type mice
• hepatic lipid uptake in male mice is increased compared to in wild-type mice
• however, pioglitazone treatment improves lipid homeostasis
|
• slight in male mice
|
• fasted male mice at 2 months
• however, random fed mice exhibit normal levels
|
• fasted and random-fed male mice at 2 months
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• mouse embryonic fibroblasts exhibit a 4-fold increase in basal glycerol release indicating increased basal lipolysis compared with wild-type cells
• however, isoprenaline-stimulated lipolysis is normal
|
adipose tissue
• in male mice
• however, pioglitazone treatment improves phenotype
|
• following induction of adipocyte differentiation, mouse embryonic fibroblasts exhibit reduced triacylglycerol levels compared with wild-type cells
• however, thiazolidinediones partially restore adipocyte function in vitro
|
• absent peri-gonadal fat pad in male mice
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
|
• near total in 2 month old male mice
|
liver/biliary system
• in male mice
|
• 2-fold in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
• in male mice
• however, pioglitazone treatment improves phenotype
|
growth/size/body
• in mice treated with pioglitazone
• however, untreated mice exhibit normal body weight
|
• in male mice
|
• 2-fold in male mice
• however, pioglitazone treatment improves phenotype
|
behavior/neurological
N |
• male mice exhibit normal activity levels
|
• at 2 months in male mice
|
digestive/alimentary system
• enlarged in male mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
congenital generalized lipodystrophy type 2 | DOID:0111136 |
OMIM:269700 |
J:200947 |